Medical therapies for non-melanoma skin cancer

Chakrabarty, Arun; Geisse, John K.

doi:10.1016/j.clindermatol.2003.12.005

Cited by 46 publications

(39 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Properly delivered, radiation therapy reaches rates of tumour control above 90% in both BCC and SCC. Different techniques of radiotherapy have been used in the treatment of NMSC: external photon or electron beam radiation therapy, brachytherapy or plesiotherapy, with acceptable outcomes in terms of local control [3][4][5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

High-dose-rate (HDR) plesiotherapy with custom-made moulds for the treatment of non-melanoma skin cancer

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

High-dose-rate (HDR) plesiotherapy with custom-made moulds for the treatment of non-melanoma skin cancer

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Complete therapeutic response rates, however, do not exceed 60%, a result which is not satisfactory in cancer treatment. Moreover, treatment is often associated with severe local irritation as well as pain and secondary infections and is not suitable for patients which exhibit extensive numbers of basal cell carcinomas [1]. Thus alternative approaches have to be looked for, which do not only increase cure rates of single lesions but allow topical drug application to larger UV -exposed skin areas, in order to eliminate both obvious skin carcinomas and minimal microlesions.…”

mentioning

confidence: 99%

Targeting human DNA polymerase α for the inhibition of keratinocyte proliferation. Part 1. Homology model, active site architecture and ligand binding

Richartz

Höltje

Brandt

et al. 2008

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

In order to understand the binding modes of human DNA polymerase a (pol a) inhibitors on a molecular level, a 3D homology model of the active site of the enzyme was proposed based on the application of molecular modelling methods and molecular dynamic simulations using available crystal coordinates of pol a relatives. Docking results for a series of known nucleotide analogue inhibitors were consistent with reported experimental binding data and offered the possibility to elucidate structure-activity relationships via investigations of active site-inhibitor interactions. Furthermore, the study could explain, at least partially, the inhibitory effect of aphidicolin on pol a. In molecular dynamics simulations, aphidicolin occupied the catalytic centre, but acted in a not truly competitive manner with respect to nucleotides. It destabilized the replicating "closed" form of the pol a and transferred the enzyme into the inactive "open" conformation. This result is consistent with recent experiments on the binding mode of aphidicolin.

show abstract

“…The 5-year recurrence rate for basal cell carcinomas is approximately 5%, although this varies with the type of treatment [15]. Although one study found almost no difference in the recurrence rate of completely excised tumors and those with tumor excision at one margin, the distance to the closest resection margin is an important predictor of recurrence [16][17][18][19]. The goal of treatment is complete excision of the tumor with preservation of surrounding structures in a way aesthetically acceptable [19,20].…”

Section: Discussionmentioning

confidence: 99%

“…Although one study found almost no difference in the recurrence rate of completely excised tumors and those with tumor excision at one margin, the distance to the closest resection margin is an important predictor of recurrence [16][17][18][19]. The goal of treatment is complete excision of the tumor with preservation of surrounding structures in a way aesthetically acceptable [19,20]. Mohs' micrographic surgery is the standard treatment for all nonmelanoma skin cancer [20][21][22].…”

Section: Discussionmentioning

confidence: 99%

An aggressive Basal Cell Carcinoma with multiple focuses and distant lung metastasis: case report

Erdem¹,

Kadıoğlu²,

Uzunlar³

et al. 2012

CMJ

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is a malignant neoplasm derived from nonkeratinizing cells that originate from the basal layer of the epidermis and it is the most common type of skin cancer in humans. Giant BCC (i.e. greater than 5 cm in diameter) is quite rare and comprises 0.5 percent of all BCC. Despite the high incidence of BCC, metastasis of this tumor is rare, with rates ranging from 0.0028% to 0.55% of all BCC cases. In this case, the tumour reached a giant size and had a pulmonary metastasis.,We aimed to emphasize that although BCC's are usually indolent; the importance of adequate surgery and chemoradiotherapy should always be considered in indicated cases. Keywords: Basal cell carcinoma, metastasis, giant size, adequate surgery ÖzetBazal hücreli karsinom (BHK) epidermisin bazal tabakasından kaynaklanan ve nonkeratinize hücrelerden oluşan en yaygın cilt tümörüdür. Dev BHK (yani çapı 5 cm'den büyük) oldukça nadirdir ve tüm BHK'ların %0,5' ini oluşturmaktadır. BHK insidansı yüksek olmasına rağmen, bu tümörün metastaz oranı tüm vakaların %0,0028-%0,55 arasında değişmektedir. Bu vakada tümör dev boyuta ulaştı ve akciğer metastazı vardı. Burada, BHK'lar genellikle yavaş seyirli olmasına rağmen gerekli vakalarda yeterli cerrahi ve kemoradyoterapinin önemini vurgulamak istedik.Anahtar sözcükler: Bazal hücreli karsinom, metastaz, dev çap, yeterli cerrahi Geliş tarihi

show abstract

Medical therapies for non-melanoma skin cancer

Cited by 46 publications

References 60 publications

High-dose-rate (HDR) plesiotherapy with custom-made moulds for the treatment of non-melanoma skin cancer

High-dose-rate (HDR) plesiotherapy with custom-made moulds for the treatment of non-melanoma skin cancer

Targeting human DNA polymerase α for the inhibition of keratinocyte proliferation. Part 1. Homology model, active site architecture and ligand binding

An aggressive Basal Cell Carcinoma with multiple focuses and distant lung metastasis: case report

Contact Info

Product

Resources

About